Literature DB >> 21799656

Liver transplantation for acute hepatic failure due to chemotherapy-induced HBV reactivation in lymphoma patients.

Timothée Noterdaeme1, Luc Longrée, Christian Bataille, Arnaud Deroover, Anne Lamproye, Jean Delwaide, Yves Beguin, Pierre Honoré, Olivier Detry.   

Abstract

Hepatitis B (HBV) reactivation induced by chemotherapy is problem encountered recently in the management of malignant diseases. Chemotherapy-induced HBV reactivation may ultimately lead to terminal acute liver failure. Liver transplantation (LT) currently remains the only definitive treatment option for such cases, but is generally denied to patients suffering from malignancy. Here, the authors describe 2 cases of cancer-free and HBV graft re-infection-free survival after LT performed for terminal liver failure arising from HBV reactivation induced by chemotherapy for advanced stage lymphoma. These 2 cases, and some other reports in the literature, may suggest that patients suffering from hematologic malignancies and terminal liver disease can be considered for LT if the prognosis of their hematologic malignancy is good.

Entities:  

Keywords:  Cancer; Chemotherapy; Contraindication; Hepatitis B virus; Liver failure; Liver transplantation

Mesh:

Substances:

Year:  2011        PMID: 21799656      PMCID: PMC3132261          DOI: 10.3748/wjg.v17.i25.3069

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  20 in total

1.  Cancer in transplant recipients.

Authors:  O Detry; P Honoré; M Meurisse; N Jacquet
Journal:  Transplant Proc       Date:  2000-02       Impact factor: 1.066

2.  Fulminant hepatic failure caused by hepatitis B virus activation after chemotherapy for breast cancer treated with liver transplantation: a case report.

Authors:  C-M Hung; L-B Jeng; W-C Lee; M-C Yu; L-M Kuo; M-F Chen
Journal:  Transplant Proc       Date:  2003-02       Impact factor: 1.066

3.  Living donor liver transplantation for acute hepatic failure caused by reactivation of hepatitis B virus infection after chemotherapy for hematologic malignancy: case reports.

Authors:  S G Kim; J M Chun; R Jin; J Y Kim; D I Won; Y J Hwang
Journal:  Transplant Proc       Date:  2010-04       Impact factor: 1.066

4.  Orthotopic liver transplantation for bone-marrow transplant-associated veno-occlusive disease and graft-versus-host disease of the liver.

Authors:  H R Rosen; P Martin; G J Schiller; M Territo; D N Lewin; C R Shackleton; R W Busuttil
Journal:  Liver Transpl Surg       Date:  1996-05

5.  Successful outcome of orthotopic liver transplantation in patients with preexisting malignant states.

Authors:  S Saigal; S Norris; P Srinivasan; P Muiesan; M Rela; N Heaton; J O'Grady
Journal:  Liver Transpl       Date:  2001-01       Impact factor: 5.799

6.  Orthotopic liver transplantation for veno-occlusive disease complicating autologous bone marrow transplantation.

Authors:  S Norris; O Crosbie; G McEntee; O Traynor; N Nolan; S McCann; J Hegarty
Journal:  Transplantation       Date:  1997-05-27       Impact factor: 4.939

7.  Hepatic rejection after orthotopic liver transplantation for hepatic veno-occlusive disease or graft-versus-host disease following bone marrow transplantation.

Authors:  A Dowlati; P Honore; P Damas; M Deprez; J Delwaide; G Fillet; Y Beguin
Journal:  Transplantation       Date:  1995-07-15       Impact factor: 4.939

8.  Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors.

Authors:  W Yeo; P K Chan; S Zhong; W M Ho; J L Steinberg; J S Tam; P Hui; N W Leung; B Zee; P J Johnson
Journal:  J Med Virol       Date:  2000-11       Impact factor: 2.327

9.  Cyclosporine induces cancer progression by a cell-autonomous mechanism.

Authors:  M Hojo; T Morimoto; M Maluccio; T Asano; K Morimoto; M Lagman; T Shimbo; M Suthanthiran
Journal:  Nature       Date:  1999-02-11       Impact factor: 49.962

Review 10.  Part II: Hodgkin's lymphoma--diagnosis and treatment.

Authors:  Volker Diehl; Roman K Thomas; Daniel Re
Journal:  Lancet Oncol       Date:  2004-01       Impact factor: 41.316

View more
  4 in total

Review 1.  Management of patients with hepatitis B who require immunosuppressive therapy.

Authors:  Jessica P Hwang; Anna S-F Lok
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-11-19       Impact factor: 46.802

2.  De novo acute hepatitis B in myeloperoxidase-specific anti-neutrophil cytoplasmic autoantibody-related microscopic polyangiitis treated with corticosteroids.

Authors:  Yoichi Iwafuchi; Yuko Oyama; Takashi Morita; Akira Kamimura; Shigeru Miyazaki; Ichiei Narita
Journal:  CEN Case Rep       Date:  2012-09-12

3.  Management of hepatitis B reactivation in patients receiving cancer chemotherapy.

Authors:  Yi-Wen Huang; Raymond T Chung
Journal:  Therap Adv Gastroenterol       Date:  2012-09       Impact factor: 4.409

Review 4.  Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy.

Authors:  Man Fai Law; Rita Ho; Carmen K M Cheung; Lydia H P Tam; Karen Ma; Kent C Y So; Bonaventure Ip; Jacqueline So; Jennifer Lai; Joyce Ng; Tommy H C Tam
Journal:  World J Gastroenterol       Date:  2016-07-28       Impact factor: 5.742

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.